The QualityStocks Daily Tuesday, December 20th, 2022

Today's Top 3 Investment Newsletters

Zacks(ICCM) $2.6000 +177.60%

MarketBeat(EVER) $13.0700 +23.19%

QualityStocks(CFMS) $3.2700 +18.05%

The QualityStocks Daily Stock List

IceCure Medical (ICCM)

QualityStocks and MarketBeat reported earlier on IceCure Medical (ICCM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

IceCure Medical Ltd (NASDAQ: ICCM) is a medical device firm that is engaged in the development and marketing of minimally invasive cryoablation therapies for the oncology and women’s health markets.

The firm has its headquarters in Caesarea, Israel and was incorporated in 2006. It operates as part of the medical equipment and supplies manufacturing industry. The firm serves consumers around the globe, with a focus on Israel, the United States, Europe, Singapore, Thailand and Hong-Kong.

The company is focused on advancing the treatment of cancerous tumors. Its proprietary 3rd generation technology makes the use of freezing temperatures i.e. liquid nitrogen, to effectively and safely destroy tumors, in a painless and quick way, thus eliminating the need for surgery.

The enterprise’s products include a cryoablation solution dubbed the ProSense System. This system uses ultrasound imaging to guide a small and thin hollow needle known as a probe into a tumor. The easy-to-use system allows the physician full control of the procedure and also cuts the procedure time short. This means that procedures can be conducted in less than half an hour, in the physician’s office. The system is a proven solution for treating benign breast tumors, which are known as fibroadenomas. This is in addition to being indicated for use in the fields of urology, gynecology, general surgery and oncology.

The company is focused on expanding the availability of ProSense globally. This is in addition to building out its clinical division and research and development division, as it creates next-generation cryoablation systems.

IceCure Medical (ICCM), closed Tuesday's trading session at $2.6, up 177.5998%, on 130,893,608 volume. The average volume for the last 3 months is 90,466 and the stock's 52-week low/high is $0.75/$4.73.

ConforMIS (CFMS)

StockMarketWatch, StreetInsider, MarketBeat, The Street, QualityStocks,, PoliticsAndMyPortfolio, Trades Of The Day, TopPennyStockMovers, BUYINS.NET, Zacks, InvestorPlace, HotOTC, Mega Stock Alerts, Daily Trade Alert, Buzz Stocks, Hit and Run Candle Sticks, OTCtipReporter, Penny Pick Finders, Barchart, PennyStockScholar, Profitable Trader Authority, Rick Saddler, Schaeffer's, StockOnion, The Online Investor and PennyStockProphet reported earlier on ConforMIS (CFMS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ConforMIS Inc. (NASDAQ: CFMS) (FRA: 308) is a medical technology firm that develops, manufactures and sells various joint replacement implants as well as personalized tibia and femoral knee implants for joint damages and the treatment of osteoarthritis.

The firm, which is based in Billerica, Massachusetts, was founded in 2004. ConforMIS markets and sells its services and products to medical facilities and hospitals using independent sales representatives, sales force and distributors located in the U.S., Australia, Germany, Spain, the United Kingdom, Hungary, Austria, Monaco, Ireland, Malaysia, Switzerland, Hong Kong and Singapore.

ConforMIS uses its iFit image-to-implant platform to create individually shaped and sized implants that fit each patient’s anatomy. This is in addition to offering customized implants that have been specifically designed to restore the natural shape of an individual’s knee.

ConforMIS products include iTotal PS, a substituting posterior cruciate ligament, iTotal CR; which is a total knee replacement implant, iUni, a uni-compartmental personalized knee replacement product to treat the lateral or medial compartment of a patient’s knee and iDuo, a bi-compartmental personalized knee replacement system. The company also provides a hip replacement product known as Conformis Hip System.

As of 2021, the firm had won FDA approval for its iTotal CR and iTotal PS systems. Data has shown that roughly a million people in the U.S. undergo joint replacement surgery every year and with these minimally traumatic implant solutions out there in the market, demand is bound to surge, significantly. This will be good for ConforMIS’ growth and stocks.

ConforMIS (CFMS), closed Tuesday's trading session at $3.27, up 18.0505%, on 90,466 volume. The average volume for the last 3 months is 259,693 and the stock's 52-week low/high is $1.20/$21.3075.

MediWound (MDWD)

MarketBeat,, StockMarketWatch, InvestorPlace, StreetAuthority Daily, MarketClub Analysis, Market Report, StockOodles, TraderPower, Zeke Truligio, The Online Investor, The Street, TopStockAnalysts, QualityStocks, TradersPro, Trading Concepts, Zacks and StreetInsider reported earlier on MediWound (MDWD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

MediWound Ltd. (NASDAQ: MDWD) (FRA: M8W) is a biopharmaceutical firm that is engaged in the development, manufacture and commercialization of new bio-therapeutic solutions for tissue regeneration and repair.

The firm has its headquarters in Yavne, Israel and was incorporated in 2001 by Marian Gorecki and Lior Rosenberg. It operates in the health care sector under the biotech and pharma sub-industry and serves patients and health care organizations in Israel as well as globally.

The company is focused on addressing the unmet needs in the severe burns and chronic wound management fields. Its objective is to offer patients and healthcare professionals innovative sterile medical devices and pharmaceutical products, which include its burn wound removal agent known as NexoBrid. The company generates most of its revenue from the U.S.

The enterprise’s NexoBrid product has been developed for the removal of damaged or dead tissue known as eschar in adults with deep full- and partial-thickness thermal burns who are in hospital burn units and burn centers. It also develops MWOC003 indicated for connective tissue disorders; a topically applied drug candidate known as MWPC005, which is in its phase 1 and 2 clinical trial evaluating its effectiveness in treating non-melanoma skin cancers and EscharEX, which recently concluded its phase 2 trials for the debridement of hard-to-heal and chronic wounds.

The company is currently working on its Biologics License Application for its NexoBrid product, which is in clinical development in North America and may soon be launched in Europe. The approval of this license will not only address the needs of many patients but also extend the company’s consumer reach, which will be good for investments.

MediWound (MDWD), closed Tuesday's trading session at $11.04, up 723.8806%, on 260,581 volume. The average volume for the last 3 months is 210,851 and the stock's 52-week low/high is $1.15/$11.04.

Inspira Technologies (IINN)

MarketClub Analysis, QualityStocks and RedChip reported earlier on Inspira Technologies (IINN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Inspira Technologies Oxy B.H.N Ltd (NASDAQ: IINN)is a specialty medical device firm that is focused on researching, developing, manufacturing and marketing respiratory support technologies that offer alternatives to invasive mechanical ventilation used to treat respiratory failure.

The firm has its headquarters in Ra’annana, Israel and was incorporated in July 2017. Prior to its name change in July 2020, the firm was known as Insense Medical Ltd. The firm serves consumers around the globe.

The company’s goal is to develop a less-invasive and cost-effective respiratory support system that can act as an alternative to the mechanical ventilation that’s currently being used to save the lives of individuals with acute respiratory failure. Acute respiratory failure happens when there’s fluid buildup in the air sacs of an individual’s lungs, thus preventing their lungs from releasing oxygen into the blood.

The enterprise’s products include its new technology dubbed ART (Augmented Respiration Technology system). This respiratory support system is made up of a portable and minimally invasive dual lumen cannula, which is usually inserted into the jugular vein. This cannula uses extra-corporeal direct blood oxygenation to boost and stabilize dropping levels of oxygen saturation. This system helps to avoid the risks associated with the use of mechanical ventilation while also allowing patients to maintain spontaneous breathing.

The company recently entered into an exclusive distribution agreement with Anita Técnica S.L., which is a technical service provider and distributor of medical equipment and supplies in Spain and Portugal. This move will facilitate the rapid penetration and adoption of the company’s ART system in the medical community in Spain, which may bring in more investors into the firm and boost the company’s growth.

Inspira Technologies (IINN), closed Tuesday's trading session at $1.2, up 17.6586%, on 211,181 volume. The average volume for the last 3 months is 129,820 and the stock's 52-week low/high is $0.98/$5.08.

IRSA Inversiones y Representaciones Sociedad Anonima (IRS)

SmarTrend Newsletters, Zacks, StreetAuthority Daily,, TradersPro, The Trading Report, StockMarketWatch, Money Morning, MarketBeat, Louis Navellier, Laissez Faire Today, InvestorPlace and internetnews reported earlier on IRSA Inversiones y Representaciones Sociedad Anonima (IRS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

IRSA Inversiones y Representaciones Sociedad Anonima (NYSE: IRS) (FRA: IRYA) (BCBA: IRSA) is a diversified real estate firm involved in a range of diversified real estate activities in Argentina.

The firm has its headquarters in Buenos Aires, Argentina and was incorporated in 1943, on April 30th. It operates as part of the real estate services industry, under the real estate sector. The firm serves consumers in Argentina.

The company operates through the Operations Center in Argentina and Operations Center in Israel segments. The Operations Center in Argentina segment operates in the offices and others, shopping malls, hotels, sales and developments, international, and financial operations, corporate and others segments. On the other hand, the Operations Center in Israel segment operates in the real estate, supermarkets, telecommunications, insurance and others segments. It generates revenues from leasing of commercial spaces in shopping malls and other spaces. The company operates as a Cresud S.A.C.I.F. y A subsidiary.

The enterprise acquires, develops and operates office buildings, shopping malls and other non-shopping mall properties primarily for rental purposes. It also acquires and operates luxury hotels under the Llao Llao, Libertador and Intercontinental names. This is in addition to developing and selling residential properties; and acquiring undeveloped land reserves for future development or sale.

The firm, which recently announced its latest financial results, remains focused on increasing its revenues from its hotels, tenants and shopping malls. This will help generate significant value for its shareholders, in addition to encouraging more investments into the firm.

IRSA Inversiones y Representaciones Sociedad Anonima (IRS), closed Tuesday's trading session at $4.95, up 0.814664%, on 129,957 volume. The average volume for the last 3 months is 3.534M and the stock's 52-week low/high is $3.16/$5.77.

Rite Aid Corporation (RAD)

StocksEarning, The Street, InvestorPlace, Schaeffer's, Kiplinger Today, MarketClub Analysis, StreetInsider, Market Report, MarketBeat, Zacks, Daily Wealth, StreetAuthority Daily, Daily Trade Alert, SmallCap Network, Trades Of The Day, Barchart, StockEarnings, SmarTrend Newsletters, The Online Investor, Greenbackers, Wealth Insider Alert, TopStockAnalysts,, The Wealth Report, StockTradersHQ, Penny Stock Rumble, Investopedia, Investor Guide, CoolPennyStocks, Market Intelligence Center Alert, ProfitableTrading, AllPennyStocks, Investors Alley, Street Insider, Daily Markets, BUYINS.NET, Trading Concepts, Stock Analyzer, StockMarketWatch, Trading Markets, Wyatt Investment Research, HotOTC, The Growth Stock Wire, Market FN, Uncommon Wisdom, SmallCapVoice, FreeRealTime, The Best Newsletters, INO Market Report, Money Morning, ChartAdvisor, Daily Profit, Wall Street Resources, Stock Rocket Report, Investing Daily, Dividend Opportunities, Market Authority, InvestorsUnderground, MarketWatch, Mega Stock Picks, CustomerService, Coattail Investor, Wealthpire Inc., StockEgg, Stockhouse, StockOodles, TradersPro, Stock Stars, Wealth Daily, TraderPower, Weekly Wizards, Money and Markets, WStreet Market Commentary,, FeedBlitz, Eagle Financial Publications, TheStockAdvisors, Top Pros' Top Picks, First Penny Picks, FNNO Newsletters and Early Bird reported earlier on Rite Aid Corporation (RAD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Rite Aid Corporation (NYSE: RAD) (FRA: RTA1) (LON: 0A6H) is a company focused on operating a chain of retail drug stores.

The firm has its headquarters in Philadelphia, Pennsylvania and was incorporated in 1962, on September 12th by Alex Grass. It operates as part of the pharmaceutical retailers industry, under the healthcare sector. The firm serves consumers in the United States.

The enterprise operates through the Pharmacy services and Retail pharmacy segments. The Pharmacy services segment offers an integrated suite of pharmacy benefit management (PBM) offerings, including specialty pharmacy, mail delivery services, technology solutions, claims adjudication, network and rebate administration and pharmacy discount programs; insurance offerings for groups and individuals; transparent and traditional pharmacy benefit management (PBM) options through its Elixir PBM. This segment serves commercial employers, health plans, labor groups, and state and local governments. On the other hand, the Retail pharmacy segment sells prescription drugs and offers a range of other pharmacy services as well as brand and generic prescription drugs. It also operates retail pharmacies and clinics; and provides healthcare services, including administering immunizations for the flu, coronavirus, shingles, and others. This is in addition to helping customers with diabetes, high blood pressure and cholesterol; and providing guidance on combating obesity and tobacco addiction. Furthermore, it also educates customers on managing medications and potential side effects; and provides healthcare coaching and disease management services to health plans and employers.

The company, which has over 2400 retail pharmacy locations in the U.S., is committed to extending its consumer reach throughout the country. This will help to better meet consumer needs while generating additional revenues for the company.

Rite Aid Corporation (RAD), closed Tuesday's trading session at $4.41, up 8.0882%, on 3,586,255 volume. The average volume for the last 3 months is 4,169 and the stock's 52-week low/high is $3.84/$15.62.


InvestorPlace, MarketBeat, QualityStocks and MarketClub Analysis reported earlier on OMNIQ Corp (OMQS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OMNIQ Corp (NASDAQ: OMQS) is a company engaged in the provision of AI-based solutions.

The firm has its headquarters in Salt Lake City, Utah and was incorporated in 1973. Prior to its name change in November 2019, the firm was known as Quest Solution Inc. It operates as part of the software-application industry, under the technology sector. The firm serves consumers in the United States.

The enterprise is party to a partnership with Hyperion Partners LLC and wireless carriers to provide mobility solutions to customers on platforms that extend the market into new mobile applications. It provides computer and machine vision image processing solutions using AI technology to deliver data collection, and real time surveillance and monitoring for supply chain management, homeland security, public safety, traffic and parking management, and access control applications. It also offers end-to-end solutions, such as packaged and configurable software; software, hardware, communications, and lifecycle management services; and mobile and wireless equipment. This is in addition to manufacturing and distributing barcode labels, tags, and ribbons, as well as RFID tags and labels. It serves Fortune 500 firms in different sectors, including healthcare, retail, food and beverage, transportation, manufacturing, distribution and logistics; and oil, gas, and chemicals, as well as government agencies.

The company, which expanded its penetration into the multi-billion dollar retail and quick serve restaurant markets using its AI-Machine vision tech, is committed to adding to their revenue opportunities. This will, in turn, boost the company’s profitability while also opening it up to new growth and investment opportunities.

OMNIQ Corp (OMQS), closed Tuesday's trading session at $4.51, even for the day, on 4,252 volume. The average volume for the last 3 months is 997,558 and the stock's 52-week low/high is $4.35/$8.75.

17 Education & Technology Group (YQ)

StreetInsider, StocksEarning, MarketClub Analysis and MarketBeat reported earlier on 17 Education & Technology Group (YQ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

17 Education & Technology Group Inc. (NASDAQ: YQ) is an education technology firm that is engaged in the provision of education and education technology services.

The firm has its headquarters in Beijing, China and was incorporated in 2012, on October 30th by Bing Yuan and Jia Wei Gan. It operates as part of the education and training services industry, under the consumer defensive sector. The firm serves consumers in the People’s Republic of China.

The company is focused on empowering in-school learning and expanding its product portfolio within its smart in-school classroom solution to encompass homework-related activities, class preparation and delivery and academic assessment. This helps deliver significant efficiency improvements to students, teachers and parents in all their key daily educational activities and enabling them to engage in ways that would be impossible using traditional offline methods.

The enterprise’s in-school plus after-school integrated model delivers data-driven teaching, learning and assessment products to teachers, students and parents. The firm offers online K-12 large-class after-school tutoring services that complement students' in-school learning. It also offers educational services comprising membership-based educational content subscriptions to à la carte workbooks, study plans, and associated services. This is in addition to providing teaching and learning SaaS solutions, such as education informatization services for education-related government entities, schools, and service providers.

The firm, which recently announced its latest financial results, is committed to exploring personalized self-directed learning products that better satisfy customer needs. This will not only increase revenues into the firm but also extend its reach across its consumer base.

17 Education & Technology Group (YQ), closed Tuesday's trading session at $2.05, off by 6.3927%, on 1,000,205 volume. The average volume for the last 3 months is 1.22M and the stock's 52-week low/high is $0.61/$3.78.

Third Harmonic Bio (THRD)

RedChip, Street Insider and MarketBeat reported earlier on Third Harmonic Bio (THRD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Third Harmonic Bio Inc. (NASDAQ: THRD) is a clinical-stage bio-pharmaceutical firm that is engaged in developing pharmaceutical products to help treat inflammatory and allergic illnesses.

The firm has its headquarters in Cambridge, Massachusetts and was incorporated in 2019, on April 25th. Prior to its name change in June 2019, the firm was known as Project IGE Inc. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers in the United States.

The company is focused on creating a breakthrough treatment for individuals living with severe inflammatory and allergy-debilitating conditions that can take a significant toll on their overall health and well-being.

The enterprise’s product pipeline is comprised of a potent and highly selective, oral small molecule wild-type KIT inhibitor dubbed THB001, which is in development for the treatment of mast cell-mediated inflammatory diseases. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a range of allergic and other inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. It has completed Phase 1a clinical trials for the formulation, which has demonstrated dose-dependent reductions of serum tryptase, a key biomarker of mast cell activity, which has been shown to correlate with clinical benefit in chronic urticaria patients.

The firm recently released its latest financial results, with its CEO noting that they remained focused on advancing the development of THB001 for the treatment of asthma and chronic hives. The success and approval of this formulation for these indications will not only benefit patients suffering from these conditions but also bring in additional revenues and investments into the firm.

Third Harmonic Bio (THRD), closed Tuesday's trading session at $4, off by 6.9767%, on 1,219,518 volume. The average volume for the last 3 months is 2.767M and the stock's 52-week low/high is $3.96/$24.595.

Peabody Energy Corporation (BTU)

The Online Investor, The Street, MarketClub Analysis, StreetInsider, Schaeffer's, InvestorPlace, Daily Wealth, MarketBeat, SmarTrend Newsletters, The Growth Stock Wire, Money Morning, QualityStocks, Hit and Run Candle Sticks, Daily Markets, Barchart, TheStockAdvisors, StreetAuthority Daily, TheStockAdvisor, TopStockAnalysts, TradersPro, Energy and Capital, Daily Trade Alert, BUYINS.NET,, Wealth Daily, Kiplinger Today, SmallCap Network, SureMoney, WStreet Market Commentary, Street Insider, Wall Street Daily, ProfitableTrading, Forbes, Trading Concepts, Market Report, The Motley Fool, Investment House, Investing Futures, The Wealth Report, Trades Of The Day, Zacks, Dividend Opportunities, Uncommon Wisdom, Dynamic Wealth Report, Investment U, Investors Alley, Wyatt Investment Research, TradingMarkets, StrategicTechInvestor, Trade of the Week, The Tycoon Report, Money and Markets, Top Pros' Top Picks, Stock Tips Network, FNNO Newsletters, Stockhouse, StockMarketWatch, StockTwits, Stock Gumshoe, Daily Stocks, Inside Investing Daily, Wealthpire Inc., Cabot Wealth, The Trading Report, Wall Street Elite, Trading Markets, Stock Beast, Investing Daily, AllPennyStocks, TheTradingReport, Today's Financial News, InvestmentHouse, Investopedia, InvestorGuide, SmallCapNetwork, Market Authority, Market Intelligence Center, Market Intelligence Center Alert, Top Stock Picks and INO Market Report reported earlier on Peabody Energy Corporation (BTU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Coal plants produce one-fifth of global greenhouse gas emissions, which means that this fuel has a greater adverse impact on the environment than any other source. We have seen many countries, especially in Europe, reduce their use of coal in favor of cleaner energies in the recent years. However, the ongoing transition from fossil fuels was not helped by the current energy crisis, and with not enough infrastructure to meet the growing demand for power, many countries reverted back to using coal.

This can be seen in coal exports into Europe from the United States, which have grown by more than 40% to help ease the shortage of heating fuel as winter approaches.

The latest data from the Census Bureau shows that the overall value of coal exports to Europe from the U.S. has increased by some 184%. This has been attributed to an increase in both the price and volume of this particular fuel.

In the period between 2007–2015, Europe had imported over one-half of all coal exports from the U.S., based on value. By last year, this had dropped to 30% before surging to almost 44% this year.

Overall, exports of coal from the United States to the world have risen by less than 1% by weight. This is mainly because America’s exports to Asia have dipped by almost 24% by volume. Asia is the second-biggest market for the fuel by continent. By value, coal exports from America to the world have risen by roughly 98% this year, which is almost five times the increase in value of all exports from the country.

Prior to this, Europe mainly relied on Russia for natural gas, as it was seen as a cleaner source of energy in comparison to coal. In 2021, natural gas made up 83% of Europe’s imports, which indicates heavy reliance on the fuel. However, since Russia invaded Ukraine earlier in February, imports of natural gas decreased significantly after Russia halted exports from Gazprom in retaliation for sanctions imposed by the United States and the EU.

With its Russian supply cut off, Europe had to find alternative sources of energy. This meant that in addition to coal, the volume of imports of liquid natural gas to Europe from the U.S. had to increase significantly.

While most of the liquid natural gas exported from the United States is shipped out via Gulf seaports after being transported from Texas, most of America’s coal originates from Kentucky, Pennsylvania and West Virginia. Thus far, the Port of Virginia has shipped out more than 41% of outbound shipments to other regions of the world.

Given that the jump in exports was more in terms of earnings collected rather than an increase in export volumes, it follows that coal producers such as Peabody Energy Corporation (NYSE: BTU) have enjoyed a good run on the market and are delivering great shareholder value at the moment.

Peabody Energy Corporation (BTU), closed Tuesday's trading session at $28.6, up 0.034977%, on 2,807,320 volume. The average volume for the last 3 months is 173,686 and the stock's 52-week low/high is $9.57/$33.29.

Kandi Vehicle Technologies Group Inc. (KNDI)

Green Car Stocks, MarketClub Analysis, InvestorPlace, Schaeffer's, QualityStocks, The Street, StockMarketWatch, Hit and Run Candle Sticks, StreetInsider, TraderPower, Greenbackers, Jason Bond, Alternative Energy, GreatStockPix, Wall Street Resources, China Stock Alerts, MarketBeat, BUYINS.NET, Investing Futures,, Money Morning, Penny Stock Rumble, ProfitableTrading, TradersPro, SmarTrend Newsletters, StreetAuthority Daily, Trades Of The Day, TradingMarkets, TopStockAnalysts, FeedBlitz, Energy and Capital, Dynamic Wealth Report, DrStockPick, Money and Markets, CRWEWallStreet, Street Insider, CRWEPicks, CRWEFinance, CoolPennyStocks, ChartAdvisor, Weekly Wizards, BullRally, BestOtc, Barchart, Daily Trade Alert, StockEgg, Profit Confidential, PennyTrader Publisher, PennyToBuck, PennyStockVille, PennyOmega, PennyInvest, SmallCapNetwork, SmallCapVoice, HotOTC, Stock Traders Chat, Market Report, MadPennyStocks, StockHotTips, InvestorsUnderground, Investors Alley, StockRich, InvestorGuide, Investor Ideas, Rick Saddler and Willy Wizard reported earlier on Kandi Vehicle Technologies Group Inc. (KNDI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

As Toyota competes to close the gap with auto sector leaders Tesla and BYD in terms of performance and pricing, it is anticipated to make some adjustments to its EV strategy in the coming years, through 2026. Individuals who are familiar with the process said this while communicating with their major suppliers.

Toyota has long been searching for strategies to help the company compete with the anticipated electric vehicles on the market for the next 10 years. However, one of the individuals stated that the planned changes would unquestionably have an impact on the already scheduled programs over the next three years.

For instance, Toyota has been reviewing its $30-billion, three-stage plan for producing and selling electric vehicles since it was announced last year, according to Reuters. The company has put on hold some ongoing projects that were announced last year. At the same time, a group of company experts led by Shigeki Terashi are seeking to advance technology and enhance performance while reducing cost in the rapidly expanding electric vehicle market. This group is tasked with developing strategies to strengthen Toyota’s electric vehicle strategy, including taking into account the possibility of replacing e-TNGA as Toyota’s new platform for electric vehicles.

The timing of this change coincides with Toyota’s insistence that the fuel-hybrid market, which it helped establish with Prius, will continue to be a key component of the switch to carbon-neutral transportation.

This EV strategy that Toyota has come up with focuses mainly on the introduction of vehicles such as the BZ4x, the company’s sole fully electric vehicle and the first in a line of all-electric vehicles called Beyond Zero. Toyota has communicated to key suppliers that the second phase of its plan will span the next few years, with vehicles based on the new e-TNGA platform under development. Such changes will probably be described to suppliers in the following year at the earliest.

According to experts, Terashi and his team are currently debating whether to abandon the three-year-old e-TNGA design, which was developed by making changes to a fuel vehicle platform, in favor of an exclusive electric vehicle platform.

Toyota is already working with Denso and Aisin suppliers to expedite the development and application of the new thermal management system, even though the two suppliers were yet to respond.

The vast majority of large EV manufacturers believe that electric vehicle sales will have surpassed their expectations by the year 2030. As a result, investors and organizations interested in a clean environment have nudged Toyota to act quickly.

As Toyota revs up its EV plans, it will have to contend with startups such as Kandi Vehicle Technologies Group Inc. (NASDAQ: KNDI) that are focused on manufacturing only electric vehicles.

Kandi Vehicle Technologies Group Inc. (KNDI), closed Tuesday's trading session at $2.44, up 6.5502%, on 173,686 volume. The average volume for the last 3 months is 381,126 and the stock's 52-week low/high is $2.00/$3.84.

Mind Medicine Inc. (MNMD)

InvestorPlace, Schaeffer's, QualityStocks, The Wealth Report, The Street, MarketBeat, The Stock Dork, MarketClub Analysis, Daily Trade Alert and Trades Of The Day reported earlier on Mind Medicine Inc. (MNMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Some psychedelic medicine developers in the United States and Canada have entered into an agreement with Clerkenwell Health in order to carry out trials on their drugs for various mental health indications in the United Kingdom. Clerkenwell Health is a clinical research organization that conducts trials for therapies for a range of mental health illnesses in London.

The drug developers hope to treat mental health conditions such as major depressive disorder, social anxiety, nicotine addiction and autism spectrum disorder as well as adjustment disorder for patients with diagnoses of terminal illnesses, including cancer.

Data from trials conducted in the United Kingdom are globally accepted. This is why many companies carry out phase I and phase II clinical trials there before seeking out larger markets.

The regulatory pathway and fast-track drug approval process in the United Kingdom allows companies to speed up their applications. Since the combined regulatory review process was implemented a few years ago, approval periods have also gotten shorter with ethics applications for fast-tracking that allow approvals in 60 days also being debuted in August this year.

The developers in question include Psyence, Mydecine, PharmAla Biotech and Mindset Pharma; these companies all hope to benefit from the UK’s fast-paced drug regulatory process.

Psyence is a biotechnology company that recently received approval from the Medicines and Healthcare Products Regulatory Agency to conduct trials on its psilocybin-assisted therapy to support patients with terminal cancer through end-of-life care. The company, which is based in Toronto, has a growing facility for hallucinogenic mushrooms in South Africa. Psycence exports these mushrooms to Canada and Portugal for research purposes.

Mydecine is focused on the development of a psilocybin-derived compound for the treatment of tobacco addiction. The company, which is based in Colorado, provided this drug to Johns Hopkins University after it was awarded a grant from the NIH, a federal health agency, for its study on smoking cessation in the United States.

Mindset Pharma is focused on the development of various products, including a compound similar to psilocybin for the treatment of major depressive disorder. Clerkenwell plans to assist Mindset with scientific advice and regulatory submission. Mindset Pharma CEO, James Lanthier, stated that the company was excited to progress its research into how second-generation psychedelic drugs could be utilized in the treatment of psychiatric and neurological disorders.

PharmAla has developed an MDMA-derived drug for the treatment of autism spectrum disorder. The company, which is the only producer of pharmaceutical-grade MDMA within North America, is based in Toronto.

Clerkenwell plans to support PharmaAla via the process of approving its trial by both U.S. and British regulators — the U.S. Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA), respectively.

With enterprises such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) making progress in studies within the United States, success for the companies conducting trials in the UK would bring more psychedelic-based options to patients in need not just in North America but around the world.

Mind Medicine Inc. (MNMD), closed Tuesday's trading session at $2.59, off by 1.8939%, on 385,668 volume. The average volume for the last 3 months is 63,073 and the stock's 52-week low/high is $2.35/$25.65.

The QualityStocks Company Corner

FingerMotion Inc. (NASDAQ: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (NASDAQ: FNGR) .

FingerMotion (NASDAQ: FNGR), a mobile data and services company, has entered into a serviceagreement with ShareIntel-Shareholder Intelligence Services. Theagreement outlines ShareIntel’s assistance in reviewing the tradinghistory of FingerMotion’s common stock for the past two years aswell as tracking trading of the stock moving forward; ShareIntelwill assist the Christian Levine Law Group and Warshaw BursteinLLP, which have each already been retained by FingerMotion.According to the announcement, ShareIntel uses DRIL-Down(TM), apatented process that aggregates and analyzes repository data fromreporting entities, broker-dealers and shareholders; the processwill support FingerMotion in its efforts to proactively trackshareholder ownership; identify parties to suspicious, aberrant orunusual trading activity; and deploy corrective action steps tohelp curtail such activity. FingerMotion may have been the targetof a market manipulation scheme involving illegal naked shortselling of its common stock over the last two years; the companyhas contracted with these three companies as it investigates andworks to expose any wrongdoing. “It is obvious when our stocktrades in multiples of the outstanding shares in a single day thatthe markets' checks and balances failed,” said FingerMotion CEOMartin Shen in the press release. “Since we know that the tradingin our stock was irregular, it is our duty to our shareholders tounderstand the magnitude of the issue, and we will leverageShareIntel's patented processes and proprietary analytics to findreporting anomalies among market makers, banks, broker-dealers andclearing firms. ShareIntel also has the ability to track shareownership and identify any suspicious, aberrant and or unusualtrading activity, which supports our continuing commitment toprotect our investors and maximize shareholder value. Based on thepedigree of our investigating firms, we believe they will be ableto help prove whether or not our company is and or has been thesubject and victim of illegal naked short selling.”

To view the full press release, visit

FingerMotion Inc. (NASDAQ: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Tuesday's trading session at $3.39, up 2.4169%, on 64,250 volume. The average volume for the last 3 months is 145,177 and the stock's 52-week low/high is $0.62/$9.795.

Recent News

Jupiter Wellness Inc. (NASDAQ: JUPW)

The QualityStocks Daily Newsletter would like to spotlight Jupiter Wellness Inc. (NASDAQ: JUPW).

Jupiter Wellness has announced that the “FDA of India” has approvedits topical treatment for psoriasis and vitiligo, with a marketlaunch to follow

The global vitiligo treatment market was valued at $1.2 billion in2018 and is expected to grow at a CAGR of 5.8%, resulting in avalue of approximately $2 billion by 2026

JW-500, a topical treatment for female sexual wellness, iscurrently in development with plans to file for pre-IND and OrphanDrug Designation within the next year

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness byresearching and developing over-the-counter (“OTC”) products andintellectual property, recently issued a Letter to Shareholders toprovide key corporate updates since the company’s last report onSeptember 15, 2022 ( In addition to updates to its clinical trial pipeline, enteringthe potentially lucrative market of Female Sexual Wellness, andobtaining or adding to its intellectual property portfolio, JupiterWellness announced that India’s equivalent of the FDA has approvedits topical treatment for psoriasis and vitiligo, with a marketlaunch within the country. The company also provided a quicksummary of recent highlights and an overview of products withcurrent dispositions.

Jupiter Wellness Inc. (NASDAQ: JUPW) is a diversified company that supports health and wellness by researching and developing over-the-counter (OTC) products and intellectual property. The company has a robust and growing portfolio of granted and pending patents to protect its proprietary products.

Jupiter Wellness’s product pipeline, backed by clinical research to ensure efficacy, addresses a range of underserved conditions. The company’s revenue is generated through a combination of OTC and consumer product sales, contract research agreements, and licensing royalties.

Jupiter Wellness was formed in 2018 and is headquartered in Jupiter, Florida.

Products with Purpose

Jupiter Wellness’s product pipeline currently targets a variety of indications with underserved needs. These include:

  • Hair Loss – Jupiter Wellness’s Minoxidil Booster is a topical treatment that’s been clinically shown to increase the enzymes needed for minoxidil to work by up to 7x over a two-week period. The product has been licensed to Taisho, a $2.6 billion revenue company and Japan’s leading seller of minoxidil products, which expects to launch it commercially in 2023. The product is licensed to India-based Cosmofix Technovation Pvt. Ltd. and Sanpellegrino Cosmetics, and additional licensing opportunities are being pursued.
  • Psoriasis & VitiligoPhotocil safely and effectively permits phototherapy treatments at home by blocking harmful radiation and permitting the passage of therapeutic UV radiation. The product has been licensed abroad and is currently being launched commercially in India by Eris Oaknet Healthcare and Cosmofix Technovation under the brand name PhotoFirst. The product is also available in the U.S., and the company is working to find new partners in dermatology for expanded distribution.
  • Jellyfish Protection SunscreenNoStingz is a topical protection from jellyfish, sea lice, and UVA/UVB rays. It provides an effective barrier against the stinging mechanism of jellyfish cnidocytes, preventing the delivery of venom to the victim. NoStingz is currently available online through Amazon and Walmart, as well as in select stores.
  • EczemaJW-100 is a pre-revenue topical treatment for atopic dermatitis (eczema). In prior studies, JW-100 cleared or reduced eczema symptoms following 2 weeks of use. Results suggest that JW-100 may potentially prove superior to existing prescription drugs. It is currently being evaluated in a Phase 3, double-blind, placebo-controlled multicenter trial.
  • BurnsJW-300 is a pre-revenue topical treatment for first-degree burns and sun exposure. In prior studies, JW-300 was shown to significantly lower the incidence of burns in patients exposed to UV radiation. It is currently being evaluated for sale as an “after sun” consumer product.
  • Cold SoresJW-400 is a pre-revenue topical treatment of herpes labialis (cold sores). A phase 1, double-blind, placebo-controlled investigational study is currently being planned for JW-400.
  • Sexual WellnessJW-500 is a pre-revenue topical treatment for female libido loss. In clinical studies, the topical formulation improved nipple sensitivity and alleviated associated sexual problems. Jupiter Wellness plans to file for a pre-IND meeting with the U.S. FDA within the next 12 months and intends to seek Orphan Drug Designation.
  • COVID-19-Induced TinnitusJW-600 is currently being evaluated in a triple-blind clinical study. Up to 15% of patients recovering from COVID-19 have experienced post-acute COVID-19-induced tinnitus

Management Team

Brian John is the CEO of Jupiter Wellness. For the past 20 years, he has been an investor and advisor to companies around the globe. He is the founder of a successful financial consulting firm specializing in helping emerging growth companies and has worked with hundreds of companies in dozens of countries over the last 25 years. Mr. John also serves on the board of directors of The Learning Center at the Els Center of Excellence – a school for children with autism in Jupiter, Florida.

Doug McKinnon is the CFO of Jupiter Wellness. His 35+ year professional career includes financial, advisory, and operational experience across a broad spectrum of industry sectors, including oil and gas, technology, cannabis, and communications. He has served in C-Level positions in both private and public sectors, including as chairman and CEO of an American-stock-exchange-traded company; as VP – Chief Administrative Officer of a $12-billion-market-cap Nasdaq-traded company; as CFO of several publicly-held U.S., Canadian and Australian companies; and as CEO/CFO of various other private enterprises.

Dr. Glynn Wilson is the Chief Scientific Officer of Jupiter Wellness. He brings to the company an extensive background of success in corporate management and product development with tenures in both multinational and start-up biotech organizations. He was formerly Head of Drug Delivery at SmithKline Beecham Pharmaceuticals; Research Area Head in Advanced Drug Delivery at Ciba-Geigy Pharmaceuticals; and Founder, CEO, and Chairman of TapImmune Inc., which became Marker Therapeutics through a merger. At TapImmune, he licensed cancer vaccine technology platforms and established the clinical pipeline.

Jupiter Wellness Inc. (NASDAQ: JUPW), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

The 2022 cannabis reform has notched sizeable wins, adding three new states into adult-use cannabis legalization.NORML emphasizes how active lawmakers have been under theprohibition status quo and are looking for new policies that wouldbuild on the cannabis reform movement. By last count, 21 stateshave legalized cannabis for adult use with a even more accessingmedical marijuana. Voters were instrumental in repealingprohibitions placed on marijuana, thus offering relief to millionssuffering from the effects of prohibition, said NORML deputy director Paul Armentano. While the focus is on legalization and reform setbacks, lawmakershave achieved some victories. California governor signed a revisedbill for the marijuana tax structure in order to remove barriers togain entry into the market and cutting off the black market.Another bill allows the governor to enter into interstate marijuanacommerce, awaiting a federal policy change. These and other reformsthat occurred in different jurisdictions around the country suggestthat the overall cannabis market is going to keep growing, andplant-touching and nonplant-ouching enterprises such as Advanced Container Technologies Inc. (OTC: ACTX) all have a chance to tap the opportunities this growth presents.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.


Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.


ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Tuesday's trading session at $0.45, even for the day, on 27 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2005/$1.42.

Recent News

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing andcommercializing innovative immunotherapeutic products primarily forthe treatment of infectious and autoimmune diseases, todayannounced the closing of its underwritten public offering withgross proceeds to the company to be $8,000,000. The offeringconsists of 1,600,000 units and pre-funded units, with each unitconsisting of one American Depositary Share (“ADS”) and twowarrants, each to purchase one ADS. Each pre-funded unit consistsof one pre-funded warrant to purchase one ADS and two warrants eachto purchase one ADS. BiondVax expects to use the net proceeds,together with its existing cash and cash equivalents, for theadvancement of its NanoAbs development program and generalcorporate purposes, which may include working capital, research anddevelopment activities, regulatory matters, capital investment orother related purposes. Aegis Capital Corp. acted as the solebook-running manager for the offering.

To view the full press release, visit

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Tuesday's trading session at $3.26, off by 5.0946%, on 17,493 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.0914/$34.90.

Recent News

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF)

The QualityStocks Daily Newsletter would like to spotlight Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF).

Eloro Resources’ Executive VP of Exploration, Bill Pearson wasrecently featured on BTV

During the interview, Pearson revealed his optimism surrounding thecompany’s ongoing exploratory works within Bolivia’s Iska Iskaproject

Eloro Resources have now drilled over 70,000 meters cumulativelyacross 102 holes whilst employing five drills

The company is now working towards publishing its maiden mineralresource estimation report alongside its NI 43-101

Two years ago, Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio ofgold and base-metal properties in Bolivia, Peru and Quebec, wastaking its initial steps towards realizing its maiden drillingcampaign within in its Iska Iska project located in southernBolivia. Today, the company believes that they may have, quiteliterally, hit pay dirt. Eloro Resources Executive VP ofExploration, Bill Pearson was recently the subject of awide-ranging interview on Business TV (“BTV”); during the questionand answer session, Pearson expressed his optimism on the company’sprospects following its recent exploratory work whilstsimultaneously suggesting that the possibility that Eloro couldpotentially uncover a world class, multi-million ounce deposit ofsilver and tin within the Iska Iska project may not be far off fromthe realm of possibility (

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) is a publicly traded exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec.

The company has an option to acquire a 99% interest in the highly prospective Iska Iska Property, classified as a silver-tin polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department of southern Bolivia. Iska Iska is a road-accessible, royalty-free property.

Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the North-Central Mineral Belt of Peru, some 50 kilometers south of Barrick’s Lagunas Norte Gold Mine and Pan American Silver’s La Arena Gold Mine. La Victoria consists of eight mining concessions and eight mining claims encompassing approximately 89 square kilometers. La Victoria has good infrastructure, with access to road, water and electricity, and is located at an altitude that ranges from 3,150 meters to 4,400 meters above sea level.

The company has a strong management and technical team working diligently to uncover the value of both Iska Iska and La Victoria. Eloro is based in Toronto, Canada.


Iska Iska – Potosi, Bolivia

Iska Iska is associated with a Miocene possibly collapsed/resurgent caldera, emplaced on Ordovician age rocks with major breccia pipes, dacitic domes and hydrothermal breccias. The property is wholly controlled by the title holder, Empresa Minera Villegas S.R.L. It is located 48 kilometers north of Tupiza city, in the Sud Chichas Province of the Department of Potosi. This is an important mineral deposit type in the prolific South Mineral Belt of Bolivia. Eloro commissioned a NI 43-101 Technical Report on Iska Iska, which was completed by Micon International Limited and is available on Eloro’s website and under its filings on SEDAR.

A fully financed drill program is currently underway on the property, situated near world-class deposits including Silver Sand, San Bartolomé, Pulacayo, San Cristobal, San Vicente, Chorolque, Tasna, Choroma and Siete Suyos. Iska Iska is in the southwest part of the Eastern Cordillera, which hosts a number of major polymetallic mines and mineral deposits. Drilling and continuous channel sampling results have demonstrated some very high metal values, especially silver and tin, within an immense system, where mineralization has been encountered in every drill hole to date. The company believes there is excellent potential for world-class bulk mineable deposits.

La Victoria – Ancash, Peru

The La Victoria project, targeting gold and silver production, is situated near world-class, low-cost gold producers Pan American Silver and Barrick Gold Corporation. Located in Ancash Department, La Victoria sits on the western slopes of the Peruvian Andes. The property is located 12 hours from Lima, with a travel distance of 600 kilometers. The nearest road accessible population centers from La Victoria are Huandoval, Pallasca and Cabana. The project includes four principal mineralized zones in Peru’s prolific North-Central Mineral Belt – San Markito, Victoria, Victoria South and Ccori Orcco – with excellent potential for gold discovery. Operations at La Victoria are planned to proceed with a 2,000-meter diamond drilling program to test targets to outline potential resources at San Markito. Trenching and sampling confirmed high silver values and veins at San Markito in 2020.

Market Outlook

According to industry association The Silver Institute, the outlook for silver demand is exceptionally promising, with global demand forecast to rise to a record high of 1.112 billion ounces in 2022. The increase will be driven by record silver industrial fabrication, which is forecast to improve by 5%, as silver’s use expands primarily in solar energy and electric vehicle (EV) manufacturing. The institute states that government commitments to carbon neutrality have resulted in a rapid expansion of green energy projects, driving record photovoltaic panel installations which are expected to lift silver demand in this segment to an all-time high in 2022.

Rising demand in the electronics industry is also boosting the demand for tin, which is primarily used in solder. The electronics and electrical industries use solders containing 40-70% tin, which provide strong and reliable joints under a variety of environmental conditions. At present, the majority of the assemblers are using patented tin-and-copper-based solders. Mordor Intelligence estimated tin demand at 387 kilotons in 2021 and forecasts demand growth of 2.5% annually through 2027. Over the medium term, surging demand from the EV market and increasing applications in the electrical and electronics industry is expected to drive the market.

Management Team

Thomas G. Larsen is CEO of Eloro. He has more than 40 years of experience in the investment industry, specializing in corporate finance and management of junior resource companies, raising in excess of C$200 million. He previously held the position of President and Chief Executive Officer of Champion Iron Limited. Prior to that, he was President and Chief Executive Officer of Champion Iron Mines Limited.

Dr. Bill Pearson is Executive VP of Exploration for Eloro. He has more than 40 years of direct experience in the exploration and production of minerals worldwide. He played an integral role in the acquisitions of Desert Sun Mining Corp. by Yamana Gold in 2006 and Central Sun Mining by B2 Gold in 2009. He was formerly VP Exploration at Desert Sun Mining and Senior VP at Central Sun Mining.

Miles Nagamatsu, CPA, is CFO at Eloro. He has over 30 years of experience in accounting, management, lending, restructurings and turnarounds. Since 1993, he has acted as a CFO of public and private companies primarily in the mineral exploration and investment management sectors. He holds a Bachelor of Commerce degree from McMaster University.

Osvaldo Arce Burgoa is General Manager at Eloro. He is a geological and mineral processing engineer with 26 years of experience in Bolivia. He is a former President of the Bolivian Geological Society, Main Technical Advisor of the National Mining Corporation (COMIBOL) and has served as exploration manager and chief geologist at various mining and exploration companies. He has authored two books on Bolivian geology and holds a doctorate in mining engineering from Tohoku University in Sendai, Japan.

Eloro Resources Ltd. (OTCQX: ELRRF), closed Tuesday's trading session at $2.51, off by 0.790514%, on 49,929 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.09/$4.46.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announcedthat dosing has begun in its human clinical nicotine studyNIC-H22-1. Current cigarette smokers are participating in the36-person human pharmacokinetic randomized, double blinded,cross-over study, wherein each person will visit the laboratory tobe dosed three times over the coming weeks. Only one oral nicotinepouch (DehydraTECH-nicotine, On! brand manufactured by Altria, orZyn brand manufactured by Swedish Match) will be administered andevaluated during each visit. The primary objectives are todetermine the quantity of nicotine in blood at various time pointsand collection of vital-sign data of temperature, blood pressure,heart rate and respiratory rate. In addition, subjectiveevaluations related to throat burn, user experience,gastrointestinal experience and more will be conducted.

To view the full press release, visit

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Tuesday's trading session at $2.32, off by 4.1322%, on 5,444 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.80/$4.94.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, today announced that its Chief Executive Officer Dr. Jun Pei and Chief Financial Officer Hull Xu will be participating in the 21st Annual J.P. Morgan Tech/AutoForum. The forum is slated to take place at the Bellagio Hotelduring CES 2023 in Las Vegas, Nevada, on Jan. 5, 2023. Cepton willparticipate in a fireside chat at the event at 2:20 p.m. PT onThursday, Jan. 5. Interested parties should visit to view a live audio webcast of the presentation.

To view the full press release, visit

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Tuesday's trading session at $1.18, off by 1.6667%, on 125,497 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.01/$80.16.

Recent News

India Globalization Capital Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital Inc. (NYSE American: IGC).

India Globalization Capital (NYSE American: IGC) today announced the filing of a life sciences presentation withthe SEC on Form 8K. The presentation, available on the SEC website aswell as published to IGC’s website, provides an overview of the company’s initiatives in lifesciences. These include IGC’s focus on low-dose THC-based drugformulation and disease treatment and its various lines ofcannabinoid-based consumer products. To view the full pressrelease, visit As the marijuana market diminishes, Canadian entities arefocusing on selling medical marijuana to patients whose employersprovide MMJ health benefits. Alberta’s Aurora Cannabis and othermarket players have taken up a benefits-focused clinical strategyeven as prices fall in the country’s broken-down, aggressiveadult-use marijuana market. But the uptake of medical cannabis benefit coverage is low. Prior to adult-use legalization, analysts expected thecoverage would be a great area for self-insured benefits plans.That didn’t manifest as expected because few have adopted thecoverage. This coverage has two types — the self-insured and the fully insured — says Mike Sullivan, an employee of Cubic Health, an employee consultancy firm. Asmore players such as India Globalization Capital Inc. (NYSE American: IGC) go a step further and develop approved cannabis-basedpharmaceuticals, the medical insurance industry is likely to movefaster along the path of covering medical marijuana forpolicyholders.

India Globalization Capital Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule ( As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products ( such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand ( that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.


IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.


The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

India Globalization Capital Inc. (NYSE American: IGC), closed Tuesday's trading session at $0.3632, off by 2.9661%, on 141,051 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3605/$1.19.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelicsto Therapeutics(R), today issued a year-end summary of its keymilestone accomplishments in 2022. “2022 was a momentous yearmarked by steady progress across our pipeline of differentiatedpsychedelic-based therapeutics and partnerships targeting mentalhealth. Most notable were the advancements of our two leadprograms, CYB003 and CYB004, into clinical stage – within less than18 months since discovery – which is a remarkable accomplishmentand a true testament to the strength of our team,” said Cybin’sChief Executive Officer Doug Drysdale. “Along with our clinicalprograms, we have continued to execute on strategic opportunitiesto strengthen our intellectual property and generate value creationthrough the expansion of our preclinical drug discovery platform.Heading into 2023, we remain committed to leading the developmentof our innovative investigational therapies to address significantunmet needs for people with mental health conditions and deliveringon key 2023 data catalysts, including top-line data from ourongoing CYB003 and CYB004 trials.”

To view the full press release, visit

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin ( Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Tuesday's trading session at $0.2865, off by 2.2184%, on 877,039 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2649/$1.29.

Recent News

MetAlert Inc. (OTC: MLRT)

The QualityStocks Daily Newsletter would like to spotlight MetAlert Inc. (OTC: MLRT).

New research has found that patient navigators increase attendance of video telehealth visits. Telehealth physician visits have significantly increased in numbersince the coronavirus pandemic. That adoption was encouraged in aneffort to contain the spread of the virus. Despite this increase,technological challenges make it hard for some patients to keeptheir visits. For their 12-week pilot program, the investigatorscollected data from 4,066 patients who used video telehealthvisits. Of the total number of patients, almost 63% were women.They divided the patients into two groups: the intervention groupand the comparator group. The intervention group was made up of1,000 patients who received phone calls from a patient navigator aday before their telehealth appointments. On the other hand, thecomparator group only received the usual reminders through text andphone. Given the way various companies such as MetAlert Inc. (OTC: MLRT) are bringing innovative products aimed at facilitating telehealth,it isn’t surprising that more people will begin to see this form ofservice provision as an attractive way to interact with medicalprofessionals.

MetAlert Inc. (OTC: MLRT) is a pioneer in location sensitive health monitoring devices (estimated $47 billion industry in 2021) and wearable technology products (industry forecast to reach $174 billion by 2030).

With over 20 years of experience and an extensive patent portfolio (30+), MetAlert is a leader for consumers/patients afflicted with Alzheimer’s, dementia, and autism (ADA). This market represents approximately 2.9% of the world’s population (approximately 34 million people in 24 developed countries). Due to specific behaviors (problems with memory, adversity to wearing unknown items, etc.) of consumers/patients in this market segment, traditional products, such as an iPhone or Fitbit, are not a practical solution. This has created a significant market with very few competitors for MetAlert.

MetAlert and its subsidiaries are engaged in designing, developing, manufacturing, distributing, and selling products and services in GPS/BLE wearable technology, personal location, wandering assistive technology, and health data collection and monitoring. The company offers a global end-to-end hardware, software, and connectivity solution, in addition to developing two-way tracking technologies, which seamlessly integrate with consumer products and enterprise applications.

Using its award-winning, patented GPS SmartSole® as a hub for collecting and transmitting data to the cloud in real-time, MetAlert is expanding its value proposition to consumers and increasing its revenue per user (RPU) while creating the largest database of health statistics for ADA consumers/patients. MetAlert generates revenue from product sales, recurring subscriptions, intellectual property (IP) licensing, and professional services. The company has international distributors servicing customers in over 35 countries and is an approved U.S. military government contractor. Its customers include public health authorities and municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes and consumers.

The company is headquartered in Los Angeles, California, with a sales office in London, England, and distributors across the globe.


  • GPS SmartSoles® HUB (launched Q4 2022) is a GPS/BLE-equipped insole that allows remote monitoring, data collection, and encrypted data transmission to the cloud.
    • Telehealth (available Q4 2022) allows access remotely to doctors and other health professionals on an as-needed basis. This service will also function as the prescribing doctor once Medicare reimbursement codes are established.
    • Concierge (available Q4 2022) provides 24/7/365 enhanced emergency response that coordinates with all relevant parties to quickly detect false alarms and escalate response as needed.
    • Bluetooth Enabled Devices (available Q1 2023) include third-party devices that collect vitals and other health data and connect with the GPS Smartsoles® HUB.
    • Artificial Intelligence (available Q1 2023) software will evaluate the Teradata of health information identifying trends and respond to preestablished alert thresholds.
  • Take-Along Tracker is a small GPS tracking device – less than three inches long – that works with 4G cellular service and will have the same “HUB” functionality as the GPS Smartsoles®. This versatile and affordable mini tracker boasts super long battery life, with up to 14 days of operation per charge.
  • RoomMate™ is a wall-mounted alert system that detects and alerts caregivers about patient behavior that could lead to falls and injuries. The system features 3D infrared and wall-mounted sensors, eliminating the need for any other physical installation or wearables. RoomMate™ offers patient privacy by design. Images are not stored, but all actions are logged. It’s a unique solution for looking after patients without intruding on their personal space.

Market Outlook

According to Grand View Research (Patient Monitoring Devices Market Size & Share Report, 2030), the global patient monitoring devices market size was valued at $47.0 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 7.8% from 2022 to 2030. The expansion of the industry can be attributed to the rise in demand for monitoring devices used to measure, distribute, record, and display a variety of biometric data, including blood pressure, temperature, and blood oxygen saturation level.

The growing number of chronic disorders, such as diabetes, stroke, and kidney disease, are driving the demand for patient monitoring devices. For instance, according to the World Health Organization (WHO), about 422 million people globally have diabetes. Likewise, the number of asthma and chronic obstructive pulmonary disease patients (COPD) is increasing rapidly.

According to the WHO, around 235 million people suffer from asthma. As a result, peak flow meters, which are used to gauge respiration rate, are increasingly used. The market for patient monitoring devices is driven by the simplicity with which it is handled, transported, and remotely accessible. Major market players are engaging in a variety of tactics to expand the industry, including partnerships, cooperation, innovation, launches, and mergers.

During the COVID-19 outbreak, social segregation and quarantining procedures were put into place worldwide. Many people avoided regular hospital visits as a result. Many people now need routine home temperature and oxygen level monitoring to maintain track of their health, thereby demanding monitoring devices at home.

Various government programs are supporting the pandemic outbreak. The FDA has granted Emergency Use Authorizations (EUAs) for a few wearables and patient monitoring devices to improve access to medicines, monitor patients more closely, and lessen the risk of SARS-CoV-2 exposure to medical professionals during the COVID-19 pandemic.

The growing popularity of wearable and remote patient monitoring devices is another factor fueling the market’s expansion. By fusing clinical symptomology with vital indicators, wearable technology helps in the diagnosis of many chronic diseases. Thus, there has been a dramatic rise in the usage of wearable technology to combat COVID-19.

The wearable medical device market is anticipated to reach $174.48 Billion by 2030, expanding at a 27.1% CAGR during the forecast period (2022-2030), according to Market Research Future.

MetAlert identifies the total addressable market for its wearable patient monitoring tech for those with Alzheimer’s, dementia, and autism at more than 34 million potential patients in North America, Europe, South Africa, and Asia.

Management Team

Patrick E. Bertagna is Founder, CEO and Chairman at MetAlert. He began his career in apparel sales in 1983 and was promoted to national sales manager within two years. In 1986, he founded his first company importing apparel from Europe and selling to U.S. retailers from JCPenney to Neiman Marcus. He has founded several technology and apparel companies, including MetAlert in 2002, which he took public in 2008. He attended Cal State University Northridge with a business major and a psychology minor.

Louis Rosenbaum is COO of MetAlert. He co-founded Global Trek Xploration and was an initial investor in MetAlert. He has successfully started companies in multiple industries, including apparel, environmental services, and the music industry, achieving annual revenues in the multi-millions of dollars. He previously was president of Elements, a women’s apparel company, and of Advanced Environmental Services.

Alex McKean is CFO at MetAlert. He is also the CFO of Encore Brands Inc., a position he has held since 2009. He has held positions as Controller and VP of Finance at 24:7 Film and, Director of FP&A/SVP at Franchise Mortgage Acceptance Company, Corporate Accounting Manager/Treasurer of Polygram Filmed Entertainment and Assistant Treasurer/Controller for State Street Bank. He holds an International MBA from Thunderbird School of Global Management and undergraduate degrees in business and political science from Trinity University.

MetAlert Inc. (OTC: MLRT), closed Tuesday's trading session at $0.269, off by 10.3333%, on 8,351 volume. The average volume for the last 3 months is 8,351 and the stock's 52-week low/high is $0.06/$1.00.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Cannabis grower and brand builder Flora Growth is a rapidly growinginternational supplier and supply chain developer aiming todistinguish itself in a highly competitive market

Following on a 604 percent YOY revenue increase for the first halfof the year, Flora continues pursuing strategic acquisitions suchas its recent all-stock deal for multi-national operator FranchiseGlobal Health

Flora also anticipates expanding its production facilities, addinga fourth by the end of this year that will provide the company withits first pharmaceutical formula operation for the Colombianwellness market

The Franchise Global Health agreement is expected to give Flora astrong presence in Germany and an introduction to Europe, adding toits export pipeline to Switzerland, the Czech Republic and theUnited States from Colombia

Legal cannabis has become the the sixth-largest cash crop in theUnited States after corn, soybeans, hay, wheat and cotton (, and voters continue to address the potentials of an expandingmarket for recreational marijuana ( Non-recreational medicinal cannabis has been legalized in 37states and continues to fuel a multi-billion dollar industry (, which is only a portion of the global market that supplies the80 percent of the world’s population using cannabis or hemp formedical treatments. For now, international annual growth rates aremore robust than the projected growth rates in the United States,according to Kiplinger ( Cannabis cultivator and global distributor Flora Growth (NASDAQ: FLGC) is a rapidly growing house of brands building customer bases anddistribution channels across international lines as it aims todistinguish itself within a highly competitive arena.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.


Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Tuesday's trading session at $0.2438, off by 5.5039%, on 605,935 volume. The average volume for the last 3 months is 605,612 and the stock's 52-week low/high is $0.23/$2.38.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, finished itsinnovative 2022 Mullen FIVE Strikingly Different Test Drive Tourwith a last stop on Dec. 16, 2022, in Charlotte, North Carolina.The tour began Oct. 27, 2022, and featured stops in nine cities inthe west, south, and southeastern parts of the country. Accordingto the announcement, the tour was very successful; the company isalready planning a follow-up spring tour with stops plannedthroughout the eastern, northwest and Midwest parts of the country.The fall tour featured the Mullen Five; the spring tour willfeature the Mullen FIVE RS, a high-performance EV sport crossoverfeaturing 1,100 horsepower, a top speed of 200 mph and accelerationfrom 0 to 60 m.p.h. in under two seconds. “We had tremendoussuccess on the first leg of the Mullen FIVE tour,” said MullenAutomotive CEO and chairman David Michery in the press release.“Every location sold out, and we received overwhelmingly positivefeedback on the Mullen FIVE. I want to personally thank everyonewho came out, often in not the best weather, to visit with us andexperience the FIVE in person.”

To view the full press release, visit

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Tuesday's trading session at $0.2262, off by 16.6544%, on 228,509,448 volume. The average volume for the last 3 months is 228.509M and the stock's 52-week low/high is $0.18/$6.05.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.